Digest Network Come funziona
Network
/
Società
Go
Non verificato

Gossamer Bio, Inc.

Di cosa scriviamo

BiotecnologiaCardiologiaFarmaceuticaMedicina - VarieSalute

37 comunicati stampa

Guarda tutti i comunicati
17/06/2026
Titoli e azioni
Biotecnologia
Farmaceutica
Salute
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0
03/06/2026
Finanza
Biotecnologia
Farmaceutica
Salute
Cardiologia
Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0
02/06/2026
Titoli e azioni
Biotecnologia
Farmaceutica
Salute
Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0
18/05/2026
Titoli e azioni
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0
18/05/2026
Finanza
Mercato azionario
Web e Social Network
Telefonia e Varie
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0
15/05/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0
17/03/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato azionario
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0
23/02/2026
Web e Social Network
Telefonia e Varie
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Cardiologia
Biotecnologia
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0
08/01/2026
Mercato azionario
Finanza
Biotecnologia
Sanità
Salute
Farmaceutica
Medicina - Varie
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0
09/12/2025
Mercato azionario
Finanza
Biotecnologia
Farmaceutica
Salute
Cardiologia
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Gossamer Bio, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0